System review and metaanalysis of the relationships between five metabolic gene polymorphisms and colorectal adenoma risk
First Online: 13 December 2011 Received: 17 September 2011 Accepted: 23 November 2011 DOI:
10.1007/s13277-011-0287-x Cite this article as: Zhao, Z., Guan, Q., Yang, F. et al. Tumor Biol. (2012) 33: 523. doi:10.1007/s13277-011-0287-x Abstract
The relationships between some metabolic (including EPHX1, GSTs and NQO1) gene polymorphisms and colorectal adenoma (CRA) risk have been commonly studied, and no conclusions are available up to now. Therefore, we quantitatively studied the relationships by a metaanalysis. The databases of Medline and Embase were retrieved updated to June 15th, 2011. Crude or adjusted odds ratio (crude OR or adjusted OR) and 95% confidence interval (95%CI) were calculated to present the strength of the associations. Overall, nine case–control studies for EPHX1 Tyr113His and His139Arg, five case–control studies for GSTM1, four studies for GSTP1 Ile105Val, two studies for GSTP1 Ala114Val, six studies for GSTT1 and four studies for NQO1 Pro187Ser were included in this metaanalysis. The results of combined analyses indicated that EPHX1 Tyr113His and His139Arg, GSTT1, GSTM1, GSTP1 Ile105Val and Ala114Val were not associated with CRA risk [crude OR (95%CI): 0.98 (0.90–1.07) and
P = 0.65 for EPHX1 His carriers vs. Tyr/Tyr; 1.05 (0.97–1.15) and z-test P = 0.21 for EPHX1 Arg carriers vs. His/His; 1.05 (0.92–1.20) and z-test P = 0.47 for GSTT1 Null vs. Present; 1.01 (0.90–1.13) and z-test P = 0.90 for GSTM1 Null vs. Present; 1.04 (0.92–1.17) and z-test P = 0.56 for G carriers vs. AA for GSTP1 Ile105Val; 0.88 (0.70–1.11) and z-test P = 0.28 for T carriers vs. CC for GSTP1 Ala114Val]. In contrast, Ser allele of NQO1 Ser187Pro might be a modest risk factor for CRA development [1.19 (1.06–1.33) and z-test P = 0.003 for Ser carriers vs. Pro/Pro]. To get more precise evidences, adjusted ORs (95%CI) for EPHX1 Tyr113His, His139Arg, GSTP1 Ile105Val and NQO1 Ser187Pro were also calculated based on adjusted ORs (95%CIs) reported in primary studies. The results still indicated that EPHX1 Tyr113His, His139Arg and GSTP1 Ile105Val were not associated with CRA risk except for NQO1 Ser187Pro. When subgroup analyses were performed for population-based case–control studies or studies in HWE for EPHX1 Tyr113His and His139Arg, and NQO1 Ser187Pro polymorphisms, the results were persistent. Although with modest limitations and biases, this metaanalysis suggests that EPHX1 Tyr113His and His139Arg, GSTT1, GSTM1, GSTP1 Ile105Val and Ala114Val polymorphisms may be not risk factors for CRA development, while Ser allele of NQO1 Ser187 Pro may be a modest risk factor for CRA development, and may be used with other genetic markers for screening CRA in the future. z-test Keywords EPHX1 GSTT1 GSTM1 GSTP1 NQO1 Gene polymorphism Colorectal adenoma Metaanalysis
Zhi-Qiang Zhao, Qing-Kai Guan and Fei-Yun Yang have made equal contributions to the study.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
Zhao P, Dai M, Chen W, Li N. Cancer trends in China. Jpn J Clin Oncol. 2010;40:281–5.
Nothlings U, Yamamoto JF, Wilkens LR, Murphy SP, Park SY, Henderson BE, et al. Meat and heterocyclic amine intake, smoking, NAT1 and NAT2 polymorphisms, and colorectal cancer risk in the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2009;18:2098–106.
Northwood EL, Elliott F, Forman D, Barrett JH, Wilkie MJ, Carey FA, et al. Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk. Pharmacogenet Genomics. 2010;20:315–26.
Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer. 1975;15:617–31.
Randi G, Edefonti V, Ferraroni M, La Vecchia C, Decarli A. Dietary patterns and the risk of colorectal cancer and adenomas. Nutr Rev. 2010;68:389–408.
Onega T, Goodrich M, Dietrich A, Butterly L. The influence of smoking, gender, and family history on colorectal adenomas. J Cancer Epidemiol. 2010;2010:509347.
Skjelbred CF, Saebo M, Hjartaker A, Grotmol T, Hansteen IL, Tveit KM, et al. Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas. BMC Cancer. 2007;7:228.
Huang WY, Chatterjee N, Chanock S, Dean M, Yeager M, Schoen RE, et al. Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2005;14:152–7.
Inoue H, Kiyohara C, Marugame T, Shinomiya S, Tsuji E, Handa K, et al. Cigarette smoking, CYP1A1 MspI and GSTM1 genotypes, and colorectal adenomas. Cancer Res. 2000;60:3749–52.
Roberts-Thomson IC, Butler WJ, Ryan P. Meat, metabolic genotypes and risk for colorectal cancer. Eur J Cancer Prev. 1999;8:207–11.
Mitrou PN, Watson MA, Loktionov AS, Cardwell C, Gunter MJ, Atkin WS, et al. Role of NQO1C609T and EPHX1 gene polymorphisms in the association of smoking and alcohol with sporadic distal colorectal adenomas: results from the UKFSS Study. Carcinogenesis. 2007;28:875–82.
Ulrich CM, Bigler J, Whitton JA, Bostick R, Fosdick L, Potter JD. Epoxide hydrolase Tyr113His polymorphism is associated with elevated risk of colorectal polyps in the presence of smoking and high meat intake. Cancer Epidemiol Biomarkers Prev. 2001;10:875–82.
Inoue H, Kiyohara C, Shinomiya S, Marugame T, Tsuji E, Handa K, et al. Glutathione S-transferase polymorphisms and risk of colorectal adenomas. Cancer Lett. 2001;163:201–6.
Zhuang W, Wu XT, Zhou Y, Liu L, Liu GJ, Wu TX, et al. Interleukin10–592 promoter polymorphism associated with gastric cancer among Asians: a meta-analysis of epidemiologic studies. Dig Dis Sci. 2010;55:1525–32.
Luchtenborg M, Weijenberg MP, Kampman E, van Muijen GN, Roemen GM, Zeegers MP, et al. Cigarette smoking and colorectal cancer: APC mutations, hMLH1 expression, and GSTM1 and GSTT1 polymorphisms. Am J Epidemiol. 2005;161:806–15.
Barker HJ, Alpert LC, Compton CC, Maslen A, Kirby GM. Loss of glutathione S-transferase (GST) mu phenotype in colorectal adenocarcinomas from patients with a GSTM1 positive genotype. Cancer Lett. 2002;177:65–74.
Tiemersma EW, Kloosterman J, Bunschoten A, Kok FJ, Kampman E. Role of EPHX genotype in the associations of smoking and diet with colorectal adenomas. IARC Sci Publ. 2002;156:491–3.
Lin HJ, Probst-Hensch NM, Louie AD, Kau IH, Witte JS, Ingles SA, et al. Glutathione transferase null genotype, broccoli, and lower prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 1998;7:647–52.
Lin HJ, Zhou H, Dai A, Huang HF, Lin JH, Frankl HD, et al. Glutathione transferase GSTT1, broccoli, and prevalence of colorectal adenomas. Pharmacogenetics. 2002;12:175–9.
Lin HJ, Probst-Hensch NM, Ingles SA, Han CY, Lin BK, Lee DB, et al. Glutathione transferase (GSTM1) null genotype, smoking, and prevalence of colorectal adenomas. Cancer Res. 1995;55:1224–6.
Tiemersma EW, Bunschoten A, Kok FJ, Glatt H, de Boer SY, Kampman E. Effect of SULT1A1 and NAT2 genetic polymorphism on the association between cigarette smoking and colorectal adenomas. Int J Cancer. 2004;108:97–103.
Tijhuis MJ, Visker MH, Aarts JM, Laan W, de Boer SY, Kok FJ, et al. NQO1 and NFE2L2 polymorphisms, fruit and vegetable intake and smoking and the risk of colorectal adenomas in an endoscopy-based population. Int J Cancer. 2008;122:1842–8.
Tijhuis MJ, Wark PA, Aarts JM, Visker MH, Nagengast FM, Kok FJ, et al. GSTP1 and GSTA1 polymorphisms interact with cruciferous vegetable intake in colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2005;14:2943–51.
Moore LE, Huang WY, Chatterjee N, Gunter M, Chanock S, Yeager M, et al. GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2005;14:1823–7.
Hou L, Chatterjee N, Huang WY, Baccarelli A, Yadavalli S, Yeager M, et al. CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use, and risk for colorectal adenoma. Carcinogenesis. 2005;26:1122–8.
Tranah GJ, Giovannucci E, Ma J, Fuchs C, Hankinson SE, Hunter DJ. Epoxide hydrolase polymorphisms, cigarette smoking and risk of colorectal adenoma in the Nurses' Health Study and the Health Professionals Follow-up Study. Carcinogenesis. 2004;25:1211–8.
Cortessis V, Siegmund K, Chen Q, Zhou N, Diep A, Frankl H, et al. A case–control study of microsomal epoxide hydrolase, smoking, meat consumption, glutathione S-transferase M3, and risk of colorectal adenomas. Cancer Res. 2001;61:2381–5.
Liu L, Zeng F, Wang K, Huang J, Xin L, Zhu PQ. Meta-analysis of the association between VEGF-634 G > C and risk of malignancy based on 23 case–control studies. J Cancer Res Clin Oncol. 2011;137:1027–36.
Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297–303.
Liu L, Zhuang W, Wang RQ, Mukherjee R, Xiao SM, Chen Z, et al. Is dietary fat associated with the risk of colorectal cancer? A meta-analysis of 13 prospective cohort studies. Eur J Nutr. 2011;50:173–84.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
Omiecinski CJ, Hassett C, Hosagrahara V. Epoxide hydrolase—polymorphism and role in toxicology. Toxicol Lett. 2000;112–113:365–70.
Li X, Hu Z, Qu X, Zhu J, Li L, Ring BZ, et al. Putative EPHX1 enzyme activity is related with risk of lung and upper aerodigestive tract cancers: a comprehensive meta-analysis. PLoS One. 2011;6:e14749.
Sims P, Grover PL, Swaisland A, Pal K, Hewer A. Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide. Nature. 1974;252:326–8.
Brown B, Avalos J, Lee C, Doolittle D. The effect of tobacco smoke, nicotine, and cotinine on the mutagenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). Mutat Res. 2001;494:21–9.
Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet. 1994;3:421–8.
Hosagrahara VP, Rettie AE, Hassett C, Omiecinski CJ. Functional analysis of human microsomal epoxide hydrolase genetic variants. Chem Biol Interact. 2004;150:149–59.
Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ. Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch Biochem Biophys. 1997;337:275–83.
Yang X, Liang SH, Weyant DM, Lazarus P, Gallagher CJ, Omiecinski CJ. The expression of human microsomal epoxide hydrolase is predominantly driven by a genetically polymorphic far upstream promoter. J Pharmacol Exp Ther. 2009;330:23–30.
Kiyohara C, Otsu A, Shirakawa T, Fukuda S, Hopkin JM. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer. 2002;37:241–56.
Lampe JW. Interindividual differences in response to plant-based diets: implications for cancer risk. Am J Clin Nutr. 2009;89:1553S–7.
Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact. 2000;129:77–97.
Joseph P, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci USA. 1994;91:8413–7.
Kuehl BL, Paterson JW, Peacock JW, Paterson MC, Rauth AM. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer. 1995;72:555–61.
Xue H, Ni P, Lin B, Xu H, Huang G. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and gastric cancer risk: a HuGE review and meta-analysis. Am J Epidemiol. 2011;173:363–75.
PubMed CrossRef Copyright information
© International Society of Oncology and BioMarkers (ISOBM) 2011